Apellis Pharmaceuticals, Inc. (APLS) Stock Overview
Explore Apellis Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Apellis Pharmaceuticals, Inc. (APLS)
Key Financials
Key Financials
Market Cap
5.3B
P/E Ratio
38.71
EPS (TTM)
$1.07
ROE
0.40%
APLS Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Apellis Pharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of APLS on the NASDAQ shows an RSI of 58.28, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $14.88 for the NASDAQ listing.
Key metrics behind Apellis Pharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of 38.71 and a market capitalization of 5.3B. Combined with our AI analysis, these give both institutional and retail investors a clear view of APLS on the NASDAQ.